|Bid||67.35 x 200|
|Ask||67.36 x 200|
|Day's range||66.96 - 67.41|
|52-week range||53.04 - 72.58|
|PE ratio (TTM)||52.36|
|Earnings date||26 Apr 2018|
|Forward dividend & yield||0.64 (0.97%)|
|1y target est||75.71|
One of the biggest providers of home care visits for the elderly and unwell has warned that it could go bust unless creditors back a rescue plan. Allied Healthcare, which cares for about 13,500 people through contracts with 150 local authorities as well as out-of-hours GP services for the NHS, is filing for a company voluntary arrangement on Monday.
Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.
Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.
Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a range of one to six global businesses.
Who Is Watching Baxter International in March 2018? For fiscal 2017, Baxter International (BAX) reported revenues of ~$10.6 billion, which represents 4.0% YoY growth on a reported basis and a 5.0% rise on an operational basis. The company has projected its annual revenues for 2018 to be 6.0%–7.0% higher year-over-year (or YoY) on a reported basis.
Who Is Watching Baxter International in March 2018? Baxter International’s (BAX) top-line performance in 4Q17 was mainly driven by increased demand for the company’s Fluid Systems’ products. Baxter International also witnessed rising demand for its cytotoxic contract manufacturing services.
Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.
Dentsply Sirona (XRAY) updated its estimates and assumptions during fiscal 2Q17 and underwent an annual impairment test of goodwill. According to company estimates, the goodwill charges associated with some of its technologies segment businesses, including CAD-CAM imaging and its treatment center, came from impairment. The company recorded nearly $1.1 billion in goodwill impairment charges in 2Q17 and $581 million in 4Q17, for a total of ~$1.67 billion in fiscal 2017. Meanwhile, the company undertook an annual impairment assessment of indefinite-lived intangible assets.
Mallinckrodt (MNK) shares gained as the company beat both earnings and revenue estimates in the fourth quarter as Inomax sales revived somewhat.
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.
Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.
Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.